Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perifosine - AEterna Zentaris

Next Previous
Drug Profile

Perifosine - AEterna Zentaris

Alternative Names: AEZS-104; D-21266; KRX-0401; NSC-639966; Perifosin; YHI-1003

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Yakult Honsha
  • Class Antineoplastics; Quaternary ammonium compounds; Radiosensitisers; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Proto oncogene protein c-akt inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gynaecological cancer
  • No development reported Glioma; Neuroblastoma; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Gastrointestinal stromal tumours; Leukaemia; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
  • 26 Apr 2022 No development reported - Phase-II for Glioma (Recurrent, Second-line therapy or greater) in USA (PO) (NDR batch 22)
  • 11 Nov 2019 Keryx Biopharmaceuticals completed a phase II trial in Glioblastoma (Recurrent, Second-line therapy of greater) in the USA (NCT00590954)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top